ACTRIMS President Sees Hope for Future Progressive MS Treatment
FEBRUARY 18, 2016
For many years there were no approved treatments for patients with primary progressive multiple sclerosis. Recently, a concerted effort has been made to change that and get this patient population the help they so badly need.
Suhayal Dhib-Jalbut, MD, from Rutgers University, who serves as the President of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) discussed work being done in this area during the organization's annual meeting in New Orleans, Louisiana. While in previous years ACTRIMS has held their meeting in conjunction with other groups, 2016 marked the first time they met as an independent entity. Jalbut said he hoped excitement from the meeting would help further propel the work being done to find treatment options for patients.